{"id":519138,"date":"2026-08-12T00:00:00","date_gmt":"2026-08-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0015-2025-biopharma-membranous-nephropathy-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-08-17T11:20:32","modified_gmt":"2026-08-17T11:20:32","slug":"dlsfmd0015-2026-biopharma-membranous-nephropathy-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0015-2026-biopharma-membranous-nephropathy-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Membranous Nephropathy &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Primary membranous nephropathy (<abbr title=\"primary membranous nephropathy\">pMN<\/abbr>), the most common type of <abbr title=\"membranous nephropathy\">MN<\/abbr>, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in nondiabetic adults, there are currently no approved therapies for <abbr title=\"primary membranous nephropathy\">pMN<\/abbr>. The treatment landscape is gradually shifting from alkylating agent-based regimens and calcineurin inhibitors toward B-cell-targeted therapies. Over the 2025-2035 period, we expect the <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> therapy market to transform through the launch of several emerging therapies. Next-generation CD20 and plasma-cell targeted agents,\u00a0BAFF- \/ APRIL-targeted therapies, and\u00a0<abbr title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitors are among the leading candidates positioned to achieve the first regulatory approval for <abbr title=\"primary membranous nephropathy\">pMN<\/abbr>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do physicians use current off-label therapies to treat the disease?<\/li>\n<li>What are the <abbr data-abbreviation-entity=\"5534\" title=\"key opinion leader\">KOL<\/abbr>s\u2019 views on late-phase candidates obinutuzumab (Roche), felzartamab (Biogen), povetacicept (Vertex Therapeutics), and zanubrutinib (BeOne Medicines)?<\/li>\n<li>How will emerging therapies influence the treatment landscape and affect prescribing decisions?<\/li>\n<li>What are the <abbr data-abbreviation-entity=\"10762\" title=\"primary membranous nephropathy\">pMN<\/abbr> therapy market\u2019s key drivers and constraints, and how will the market evolve over the forecast period?<\/li>\n<li>What are the unmet needs in <abbr data-abbreviation-entity=\"10762\" title=\"primary membranous nephropathy\">pMN<\/abbr>, and how likely are they to be fulfilled during the forecast period?<\/li>\n<\/ul>\n<div>\n<p><strong>Geography: <\/strong>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<\/div>\n<div>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading nephrologists. Survey data collected for this and other Clarivate research.<\/p>\n<\/div>\n<div>\n<p><strong>Epidemiology: <\/strong>Diagnosed incidence of <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> by country, clinically and market-relevant drug-treatable populations<\/p>\n<\/div>\n<div>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key membranous nephropathy therapies through 2035, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<\/div>\n<div>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<\/div>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-519138","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/519138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=519138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}